Osimertinib

Cost comparison of osimertinib plus platinum-pemetrexed versus amivantamab plus lazertinib for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.

Journal: Journal of medical economics

Published: April 13, 2026

A multi-omics approach to identify the impact of miR-411ed on NSCLC TKI resistance.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

Evaluating Tumor Burden as a Predictive Biomarker for Epidermal Growth Factor Receptor Targeted Kinase Inhibitor Therapy in Advanced Non-Small Cell Lung Cancer.

Journal: JCO precision oncology

Published: April 09, 2026

Corrigendum to "Cost-effectiveness of first-line osimertinib informed by electronic medical records via text-mining: a real-world Italian case study of EGFR-mutated advanced NSCLC patients": [ESMO Real World Data and Digital Oncology Volume 10, December 2025, 100198].

Journal: ESMO real world data and digital oncology

Published: April 03, 2026

National Delphi consensus on perioperative and locally advanced NSCLC management in Colombia.

Journal: Expert review of anticancer therapy

Published: April 01, 2026

Shengmai San improves osimertinib resistance of non-small cell lung cancer cells by regulating the lactate/Wnt/β-catenin/LDHA pathway

Journal: Nan fang yi ke da xue xue bao = Journal of Southern Medical University

Published: March 26, 2026

Primary cilia promote resistance to EGFR tyrosine kinase inhibitor, osimertinib, in non-small cell lung cancer.

Journal: bioRxiv : the preprint server for biology

Published: March 18, 2026

AKR1C3 Inhibition: A Strategy to Reverse Osimertinib Resistance in Non-small Cell Lung Cancer.

Journal: Journal of medicinal chemistry

Published: March 13, 2026

Recalcitrant thyroid eye disease responsive to targeted EGFR inhibition in a patient with lung adenocarcinoma: a case report.

Journal: Orbit (Amsterdam, Netherlands)

Published: March 12, 2026

Long-Term Survival Achieved by Combined Surgical Resection and Immunotherapy for Recurrent Adrenal Oligometastasis of Lung Adenocarcinoma: A Case Study.

Journal: Cureus

Published: March 09, 2026

Thoracic oncology

Journal: Deutsche medizinische Wochenschrift (1946)

Published: March 09, 2026

Identification of SORD as A Key Gene Mediating Osimertinib Primary Resistance  in EGFR-Mutant Lung Adenocarcinoma via Machine Learning and Methylomics

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer

Published: March 04, 2026

Cost comparison of osimertinib plus platinum-pemetrexed versus amivantamab plus lazertinib for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.

Cost comparison of osimertinib plus platinum-pemetrexed versus amivantamab plus lazertinib for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.

A multi-omics approach to identify the impact of miR-411ed on NSCLC TKI resistance.

A multi-omics approach to identify the impact of miR-411ed on NSCLC TKI resistance.

Evaluating Tumor Burden as a Predictive Biomarker for Epidermal Growth Factor Receptor Targeted Kinase Inhibitor Therapy in Advanced Non-Small Cell Lung Cancer.

Evaluating Tumor Burden as a Predictive Biomarker for Epidermal Growth Factor Receptor Targeted Kinase Inhibitor Therapy in Advanced Non-Small Cell Lung Cancer.

Corrigendum to "Cost-effectiveness of first-line osimertinib informed by electronic medical records via text-mining: a real-world Italian case study of EGFR-mutated advanced NSCLC patients": [ESMO Real World Data and Digital Oncology Volume 10, December 2025, 100198].

Corrigendum to "Cost-effectiveness of first-line osimertinib informed by electronic medical records via text-mining: a real-world Italian case study of EGFR-mutated advanced NSCLC patients": [ESMO Real World Data and Digital Oncology Volume 10, December 2025, 100198].

National Delphi consensus on perioperative and locally advanced NSCLC management in Colombia.

National Delphi consensus on perioperative and locally advanced NSCLC management in Colombia.

Shengmai San improves osimertinib resistance of non-small cell lung cancer cells by regulating the lactate/Wnt/β-catenin/LDHA pathway

Shengmai San improves osimertinib resistance of non-small cell lung cancer cells by regulating the lactate/Wnt/β-catenin/LDHA pathway

Primary cilia promote resistance to EGFR tyrosine kinase inhibitor, osimertinib, in non-small cell lung cancer.

Primary cilia promote resistance to EGFR tyrosine kinase inhibitor, osimertinib, in non-small cell lung cancer.

AKR1C3 Inhibition: A Strategy to Reverse Osimertinib Resistance in Non-small Cell Lung Cancer.

AKR1C3 Inhibition: A Strategy to Reverse Osimertinib Resistance in Non-small Cell Lung Cancer.

Recalcitrant thyroid eye disease responsive to targeted EGFR inhibition in a patient with lung adenocarcinoma: a case report.

Recalcitrant thyroid eye disease responsive to targeted EGFR inhibition in a patient with lung adenocarcinoma: a case report.

Long-Term Survival Achieved by Combined Surgical Resection and Immunotherapy for Recurrent Adrenal Oligometastasis of Lung Adenocarcinoma: A Case Study.

Long-Term Survival Achieved by Combined Surgical Resection and Immunotherapy for Recurrent Adrenal Oligometastasis of Lung Adenocarcinoma: A Case Study.

Thoracic oncology

Thoracic oncology

Identification of SORD as A Key Gene Mediating Osimertinib Primary Resistance in EGFR-Mutant Lung Adenocarcinoma via Machine Learning and Methylomics

Identification of SORD as A Key Gene Mediating Osimertinib Primary Resistance in EGFR-Mutant Lung Adenocarcinoma via Machine Learning and Methylomics

Identification of SORD as A Key Gene Mediating Osimertinib Primary Resistance  in EGFR-Mutant Lung Adenocarcinoma via Machine Learning and Methylomics

Identification of SORD as A Key Gene Mediating Osimertinib Primary Resistance  in EGFR-Mutant Lung Adenocarcinoma via Machine Learning and Methylomics